BG101822A - Метод за получаване на орални дозирани форми, съдържащи бета-лактамов антибиотик - Google Patents

Метод за получаване на орални дозирани форми, съдържащи бета-лактамов антибиотик

Info

Publication number
BG101822A
BG101822A BG101822A BG10182297A BG101822A BG 101822 A BG101822 A BG 101822A BG 101822 A BG101822 A BG 101822A BG 10182297 A BG10182297 A BG 10182297A BG 101822 A BG101822 A BG 101822A
Authority
BG
Bulgaria
Prior art keywords
dosage forms
oral dosage
lactam antibiotic
forms containing
containing beta
Prior art date
Application number
BG101822A
Other languages
English (en)
Other versions
BG63528B1 (bg
Inventor
Jan SUBRANDS
Koutrik Cornelis Van
Original Assignee
Astellas Pharma Europe B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Europe B.V. filed Critical Astellas Pharma Europe B.V.
Publication of BG101822A publication Critical patent/BG101822A/bg
Publication of BG63528B1 publication Critical patent/BG63528B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Методът е приложим за получаване на гранулат, съдържащ орално действащ бета-лактамов антибиотик с разтворимост във вода 1 : 10. Той се състои в навлажняване на компонентите и приготвяне на гранулата с воден разтвор, който не съдържа съществени количества от свързващо средство за мокро гранулиране. Изобретението се отнася също до орални дозирани форми, съдържащи посочения антибиотик в гранулна форма, целулозен продукт и разпадащо средство, които се диспергират бързо, когато се поставят във воднасреда. Изобретението се отнася и до метод за приготвяне на дозираните форми.
BG101822A 1995-02-08 1997-08-08 Метод за получаване на орални дозирани форми, съдържащи бета-лактамов антибиотик BG63528B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200313 1995-02-08
PCT/EP1996/000547 WO1996024337A1 (en) 1995-02-08 1996-02-08 ORAL DOSAGE-FORMS CONTAINING A β-LACTAM ANTIBIOTIC

Publications (2)

Publication Number Publication Date
BG101822A true BG101822A (bg) 1998-04-30
BG63528B1 BG63528B1 (bg) 2002-04-30

Family

ID=8220003

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101822A BG63528B1 (bg) 1995-02-08 1997-08-08 Метод за получаване на орални дозирани форми, съдържащи бета-лактамов антибиотик

Country Status (19)

Country Link
US (1) US5948422A (bg)
EP (1) EP0801559B1 (bg)
CN (1) CN1125636C (bg)
AT (1) ATE216576T1 (bg)
AU (1) AU4789696A (bg)
BG (1) BG63528B1 (bg)
BR (1) BR9607189A (bg)
CZ (1) CZ293718B6 (bg)
DE (1) DE69620866T2 (bg)
DK (1) DK0801559T3 (bg)
EA (2) EA003736B1 (bg)
ES (1) ES2175073T3 (bg)
HU (1) HU227938B1 (bg)
MX (1) MX9706062A (bg)
NO (1) NO319993B1 (bg)
PL (1) PL186386B1 (bg)
PT (1) PT801559E (bg)
WO (1) WO1996024337A1 (bg)
ZA (1) ZA961018B (bg)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
EP0912169A2 (en) 1996-07-16 1999-05-06 Gist-Brocades B.V. $g(b)-LACTAM GRANULES FREE OF ORGANIC SOLVENTS
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
PT1058538E (pt) * 1998-03-06 2002-11-29 Eurand Int Comprimidos de desintegracao rapida
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
DE19922537A1 (de) * 1999-05-10 2000-11-16 Roland Bodmeier Darreichungsform zur Applikation in Körperöffnungen
CA2423329A1 (en) * 2000-09-22 2003-03-20 Takeda Chemical Industries, Ltd. Solid preparations
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
EP1368003A4 (en) * 2001-02-05 2004-05-12 Scherer Technologies Inc R P METHODS AND COMPOSITIONS FOR REDUCING THE TASTE OF PHARMACEUTICAL ACTIVE SUBSTANCES
WO2003077842A2 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Palatable oral suspension and method
DE60334391D1 (de) * 2002-10-02 2010-11-11 Meiji Seika Kaisha Antibakterielle medizinische zusammensetzung mit erhöhtem oralem absorptionsvermögen
JP4708795B2 (ja) * 2002-12-20 2011-06-22 ニコノヴァム エービー 物理的および化学的に安定なニコチン−含有粒状物質
EP1648380B1 (en) * 2003-07-03 2015-04-08 Sertoli Technologies, LLC Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
KR101432313B1 (ko) * 2005-11-17 2014-08-20 노파르티스 아게 약제학적 조성물
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
AU2007278850B2 (en) * 2006-07-28 2013-06-06 Sertocell Biotechnology (Us) Corp. Adult sertoli cells and uses thereof
WO2010031552A1 (en) * 2008-09-17 2010-03-25 Niconovum Ab Process for preparing snuff composition
CA2746768A1 (en) * 2008-12-17 2010-07-08 Altheus Therapeutics, Inc. Enema formulations
WO2023204773A1 (en) * 2022-04-20 2023-10-26 Bilim Ilac Sanayii Ve Ticaret A.S. Tablet formulations for the treatment of urinary system infections and method for the preparation of such formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3344030A (en) * 1964-06-15 1967-09-26 American Home Prod Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables
DE2251249A1 (de) * 1972-10-19 1974-05-02 Hoechst Ag Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten
DE2251250C3 (de) * 1972-10-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
ATE108996T1 (de) * 1988-02-25 1994-08-15 Brocades Pharma Bv Verfahren zur herstellung eines pharmazeutischen granulats.
US5643591A (en) * 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
JPH09512015A (ja) * 1994-04-13 1997-12-02 リサーチ・コーポレイション・テクノロジーズ・インコーポレイテッド セルトーリ細胞および同種移植片または異種移植片を用いる疾患処置方法
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin

Also Published As

Publication number Publication date
EP0801559B1 (en) 2002-04-24
CN1173816A (zh) 1998-02-18
DE69620866T2 (de) 2003-02-27
WO1996024337A1 (en) 1996-08-15
HUP9801677A2 (hu) 1998-11-30
HU227938B1 (en) 2012-06-28
EA199900205A1 (ru) 2000-06-26
DE69620866D1 (de) 2002-05-29
NO973646L (no) 1997-09-11
BR9607189A (pt) 1997-11-11
AU4789696A (en) 1996-08-27
PL186386B1 (pl) 2004-01-30
PL321567A1 (en) 1997-12-08
ATE216576T1 (de) 2002-05-15
EA003736B1 (ru) 2003-08-28
MX9706062A (es) 1997-10-31
CZ293718B6 (cs) 2004-07-14
CZ230297A3 (en) 1997-11-12
US5948422A (en) 1999-09-07
BG63528B1 (bg) 2002-04-30
CN1125636C (zh) 2003-10-29
DK0801559T3 (da) 2002-06-17
EP0801559A1 (en) 1997-10-22
EA199700093A1 (ru) 1998-02-26
ES2175073T3 (es) 2002-11-16
NO319993B1 (no) 2005-10-10
ZA961018B (en) 1997-08-08
PT801559E (pt) 2002-09-30
EA000361B1 (ru) 1999-06-24
NO973646D0 (no) 1997-08-07
HUP9801677A3 (en) 1999-05-28

Similar Documents

Publication Publication Date Title
BG101822A (bg) Метод за получаване на орални дозирани форми, съдържащи бета-лактамов антибиотик
MY116124A (en) Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
HUP9802259A3 (en) 1,4,5-substituted imidazole compounds, pharmaceutical compounds containing them, process for producing them and their use
HUP9900625A3 (en) Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds
HUP9602932A3 (en) Substituted imidazolidine-2,4-dion compounds, their use as pharmaceutical agent and process for their preparation
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
GR3036279T3 (en) Utilization of benzazols as UV-absorbers, new benzazoles and process for their preparation.
IL125404A0 (en) 4-amino-pyrimidine derivatives medicaments containing these compounds their use and process for their production
ZA973647B (en) Inhibitors of metalloprotease, process for preparing them and pharmaceutical compositions containing them.
HUP0002050A3 (en) Substituted imidazole compounds, process for producing them, pharmaceutical compositions containing them and their use
HU9802653D0 (en) Substituted imidazolidine derivatives, process for producing them, their use, and pharmaceutical compositions containing them
HUP0000941A3 (en) Sulfamide derivatives, process for producing them, pharmaceutical compositions containing them and their use
ZA927205B (en) Acylals of imidazole-5-carboxylic acid derivatives, process for their preparation and their use.
HU9601321D0 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, their use as pharmaceutical compositions or diagnostica, and pharmaceutical compositions containing them
HUP9901260A3 (en) Optically active phenylpyrimidine derivative as analgesic agent, process for producing it, pharmaceutical composition containing it and its intermediate
HUP9602640A2 (en) Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds.
AU1530195A (en) Halogenated derivatives of 2,3'-(o)-cyclocytidine compounds and process for production thereof
HUP9601680A3 (en) Benzisothiazolyl-substituted aminomethyl-chromanes, pharmaceutical compositions containing the same, process for their preparation and use of the compounds
HU9503212D0 (en) Composition of polyols, process for preparation and use thereof
ZA969319B (en) Derivatives of imidazole n-benzyldioxole, their preparation process, their use as medicaments, pharmaceutical composition and new use.
SI0763535T1 (en) Piperidinylmethyloxazolidin-2-one derivatives, their preparation and their use as pharmacological active CNS compounds
ZA949347B (en) 1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceutical agents containing these compounds and process for their production.
EP0533056A3 (en) Substituted aminopropanes, process for their preparation and their use as antimycotic agents
HK1025558A1 (en) Optically active 2-aminotetraline, process for its preparation and pharmaceutical compositions containing same, active in preventing and treating septic shock